| Discovery and resupply of pharmacologically active plant-derived natural products: A review AG Atanasov, B Waltenberger, EM Pferschy-Wenzig, T Linder, ... Biotechnology advances 33 (8), 1582-1614, 2015 | 3002 | 2015 |
| Natural products in drug discovery: advances and opportunities AG Atanasov, SB Zotchev, VM Dirsch, CT Supuran Nature reviews Drug discovery 20 (3), 200-216, 2021 | 2922 | 2021 |
| Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review L Wang, B Waltenberger, EM Pferschy-Wenzig, M Blunder, X Liu, ... Biochemical pharmacology 92 (1), 73-89, 2014 | 706 | 2014 |
| Why drugs fail-a study on side effects in new chemical entities D Schuster, C Laggner, T Langer Current pharmaceutical design 11 (27), 3545-3559, 2005 | 491 | 2005 |
| How to optimize shape-based virtual screening: choosing the right query and including chemical information J Kirchmair, S Distinto, P Markt, D Schuster, GM Spitzer, KR Liedl, ... Journal of chemical information and modeling 49 (3), 678-692, 2009 | 223 | 2009 |
| Pharmacophore models and pharmacophore-based virtual screening: concepts and applications exemplified on hydroxysteroid dehydrogenases T Kaserer, KR Beck, M Akram, A Odermatt, D Schuster Molecules 20 (12), 22799-22832, 2015 | 193 | 2015 |
| The discovery of new 11β-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening D Schuster, EM Maurer, C Laggner, LG Nashev, T Wilckens, T Langer, ... Journal of medicinal chemistry 49 (12), 3454-3466, 2006 | 166 | 2006 |
| Honokiol: a non-adipogenic PPARγ agonist from nature AG Atanasov, JN Wang, SP Gu, J Bu, MP Kramer, L Baumgartner, ... Biochimica et Biophysica Acta (BBA)-General Subjects 1830 (10), 4813-4819, 2013 | 156 | 2013 |
| In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens JM Rollinger, D Schuster, B Danzl, S Schwaiger, P Markt, M Schmidtke, ... Planta medica 75 (03), 195-204, 2009 | 149 | 2009 |
| Parallel screening: a novel concept in pharmacophore modeling and virtual screening TM Steindl, D Schuster, C Laggner, T Langer Journal of chemical information and modeling 46 (5), 2146-2157, 2006 | 142 | 2006 |
| The Protein Data Bank (PDB), its related services and software tools as key components for in silico guided drug discovery J Kirchmair, P Markt, S Distinto, D Schuster, GM Spitzer, KR Liedl, ... Journal of medicinal chemistry 51 (22), 7021-7040, 2008 | 123 | 2008 |
| Endogenous metabolites of vitamin E limit inflammation by targeting 5-lipoxygenase H Pein, A Ville, S Pace, V Temml, U Garscha, M Raasch, K Alsabil, ... Nature communications 9 (1), 3834, 2018 | 121 | 2018 |
| Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling A Vuorinen, D Schuster Methods 71, 113-134, 2015 | 121 | 2015 |
| Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors D Schuster, C Laggner, TM Steindl, A Palusczak, RW Hartmann, T Langer Journal of chemical information and modeling 46 (3), 1301-1311, 2006 | 118 | 2006 |
| Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein JM Rollinger, TM Steindl, D Schuster, J Kirchmair, K Anrain, EP Ellmerer, ... Journal of medicinal chemistry 51 (4), 842-851, 2008 | 104 | 2008 |
| Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates J Kirchmair, S Distinto, D Schuster, G Spitzer, T Langer, G Wolber Current medicinal chemistry 15 (20), 2040-2053, 2008 | 101 | 2008 |
| The identification of ligand features essential for PXR activation by pharmacophore modeling D Schuster, T Langer Journal of chemical information and modeling 45 (2), 431-439, 2005 | 100 | 2005 |
| Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin AM Schaible, H Traber, V Temml, SM Noha, R Filosa, A Peduto, ... Biochemical pharmacology 86 (4), 476-486, 2013 | 98 | 2013 |
| Why is 11β-hydroxysteroid dehydrogenase type 1 facing the endoplasmic reticulum lumen?: Physiological relevance of the membrane topology of 11β-HSD1 A Odermatt, AG Atanasov, Z Balazs, RAS Schweizer, LG Nashev, ... Molecular and cellular endocrinology 248 (1-2), 15-23, 2006 | 98 | 2006 |
| The UV-filter benzophenone-1 inhibits 17β-hydroxysteroid dehydrogenase type 3: virtual screening as a strategy to identify potential endocrine disrupting chemicals LG Nashev, D Schuster, C Laggner, S Sodha, T Langer, G Wolber, ... Biochemical pharmacology 79 (8), 1189-1199, 2010 | 96 | 2010 |
